{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Female+Reproductive+System+Carcinoma&page=2", "query": { "condition": "Recurrent Female Reproductive System Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Female+Reproductive+System+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T07:48:29.958Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00005807", "title": "Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "BMS-247550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 40, "start_date": "2000-07", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-06-10T07:48:29.958Z", "location_count": 2, "location_summary": "New York, New York • The Bronx, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005807" }, { "nct_id": "NCT03836352", "title": "Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Hepatocellular Carcinoma", "Non-small Cell Lung Cancer", "Bladder Cancer", "Microsatellite Instability-High" ], "interventions": [ { "name": "DPX-Survivac", "type": "OTHER" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2018-12-21", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-06-10T07:48:29.958Z", "location_count": 15, "location_summary": "Tucson, Arizona • Los Angeles, California • Boca Raton, Florida + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03836352" }, { "nct_id": "NCT00003538", "title": "Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "graft versus host disease prophylaxis/therapy", "type": "BIOLOGICAL" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": null, "start_date": "1997-03", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2014-05-02", "last_synced_at": "2026-06-10T07:48:29.958Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003538" }, { "nct_id": "NCT00245050", "title": "Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Drug/Agent Toxicity by Tissue/Organ", "Endometrial Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer" ], "interventions": [ { "name": "pyridoxine hydrochloride", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DRUG" }, { "name": "doxorubicin HCL liposome", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 34, "start_date": "2004-04", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2011-12-30", "last_synced_at": "2026-06-10T07:48:29.958Z", "location_count": 8, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00245050" }, { "nct_id": "NCT00003946", "title": "Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "danazol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-10", "last_synced_at": "2026-06-10T07:48:29.958Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003946" }, { "nct_id": "NCT00897442", "title": "Collecting Tumor Samples From Patients With Gynecological Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Borderline Ovarian Clear Cell Tumor", "Borderline Ovarian Serous Tumor", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Small Cell Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Childhood Embryonal Rhabdomyosarcoma", "Childhood Malignant Ovarian Germ Cell Tumor", "Endometrioid Stromal Sarcoma", "Gestational Trophoblastic Tumor", "Malignant Mesothelioma", "Malignant Ovarian Epithelial Tumor", "Melanoma", "Neoplasm of Uncertain Malignant Potential", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Paget Disease of the Vulva", "Recurrent Cervical Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Stage I Ovarian Cancer", "Stage I Uterine Corpus Cancer", "Stage I Vaginal Cancer", "Stage I Vulvar Cancer", "Stage IA Cervical Cancer", "Stage IA Fallopian Tube Cancer", "Stage IA Ovarian Cancer", "Stage IA Ovarian Germ Cell Tumor", "Stage IB Cervical Cancer", "Stage IB Fallopian Tube Cancer", "Stage IB Ovarian Cancer", "Stage IB Ovarian Germ Cell Tumor", "Stage IC Fallopian Tube Cancer", "Stage IC Ovarian Cancer", "Stage IC Ovarian Germ Cell Tumor", "Stage II Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage II Vaginal Cancer", "Stage II Vulvar Cancer", "Stage IIA Cervical Cancer", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Cancer", "Stage IIA Ovarian Germ Cell Tumor", "Stage IIB Cervical Cancer", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Cancer", "Stage IIB Ovarian Germ Cell Tumor", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Cancer", "Stage IIC Ovarian Germ Cell Tumor", "Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor", "Stage III Cervical Cancer", "Stage III Uterine Corpus Cancer", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Stage IV Uterine Corpus Cancer", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Uterine Corpus Cancer", "Uterine Corpus Leiomyosarcoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 275, "start_date": "1992-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-06-10T07:48:29.958Z", "location_count": 187, "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897442" }, { "nct_id": "NCT01010126", "title": "Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Hepatocellular Carcinoma", "Advanced Adult Hepatocellular Carcinoma", "Endometrial Serous Adenocarcinoma", "Localized Non-Resectable Adult Liver Carcinoma", "Lung Carcinoid Tumor", "Malignant Pancreatic Gastrinoma", "Malignant Pancreatic Glucagonoma", "Malignant Pancreatic Insulinoma", "Malignant Pancreatic Somatostatinoma", "Metastatic Digestive System Neuroendocrine Tumor G1", "Ovarian Carcinosarcoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Surface Papillary Adenocarcinoma", "Pancreatic Alpha Cell Adenoma", "Pancreatic Beta Cell Adenoma", "Pancreatic Delta Cell Adenoma", "Pancreatic G-Cell Adenoma", "Pancreatic Polypeptide Tumor", "Recurrent Adult Liver Carcinoma", "Recurrent Digestive System Neuroendocrine Tumor G1", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Neuroendocrine Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Regional Digestive System Neuroendocrine Tumor G1", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IIIC Uterine Corpus Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer", "Uterine Carcinosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2009-09-08", "completion_date": "2017-03-13", "has_results": true, "last_update_posted_date": "2019-01-25", "last_synced_at": "2026-06-10T07:48:29.958Z", "location_count": 57, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 44 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01010126" }, { "nct_id": "NCT00462826", "title": "VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Endometrial Carcinoma" ], "interventions": [ { "name": "ziv-aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 49, "start_date": "2007-11", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-06-10T07:48:29.958Z", "location_count": 67, "location_summary": "Hartford, Connecticut • New Britain, Connecticut • Washington D.C., District of Columbia + 43 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00462826" }, { "nct_id": "NCT04315233", "title": "Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Recurrent Ovarian Carcinoma" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Belinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-05-03", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-06-10T07:48:29.958Z", "location_count": 2, "location_summary": "Salt Lake City, Utah • Fairfax, Virginia", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04315233" }, { "nct_id": "NCT00019916", "title": "Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "p53 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2000-06", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-06-10T07:48:29.958Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019916" } ] }